Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ML43165 - Single Arm Phase 2 Trial of an FDA Approved Anti-CD19 CAR-T Therapy Followed by Mosunetuzumab and Polatuzumab Consolidation for the Treatment of Refractory/Relapsed Aggressive NHL.

NCT05260957 is registered in ClinicalTrials.gov with Lazaros Lekakis as lead sponsor.

NCT NCT05260957
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05260957 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ML43165 - Single Arm Phase 2 Trial of an FDA Approved Anti-CD19 CAR-T Therapy Followed by Mosunetuzumab and Polatuzumab Consolidation for the Treatment of Refractory/Relapsed Aggressive NHL.
Lead sponsor
Lazaros Lekakis
Phase
Phase 2
Overall status
Recruiting
Start date
December 14, 2022
Completion date
December 31, 2028
Enrollment
22 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aggressive non-hodgkin lymphoma, refractory non-hodgkin lymphoma, relapsed non hodgkin lymphoma